CellCAN: A unique enabler of regenerative medicine and cell therapy in Canada

Denis Claude Roy, Anne Marie Alarco, Rosario Isasi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Regenerative Medicine and Cell Therapy (RMCT) is paving the way for the most innovative and promising medical breakthroughs of the 21st century. Indeed, its curative potential is immense and builds on the already proven benefits of stem cell transplantation. Successful and broad clinical implementation of RMCT, as well as reaping of its full social and economic benefits, is contingent on the resolution of a range of issues. The CellCAN network, a not-for-profit corporation, was created to tackle these challenges, gathering the key forces of the numerous Canadian organizations involved in basic research, assay development, manufacturing, clinical research, clinical trials, legal and ethical regulations, and policies, all working to move RMCT forward. CellCAN creates a national enterprise by bringing together a community of renowned researchers, industries, clinicians, funders and regulators, and aligning it with cell-handling facilities involved in processing cell products and other products for cell therapy clinical trials to ensure capacity and know-how for stem cell research and efficient execution of cell therapy clinical trials. CellCAN is uniquely positioned to accelerate the implementation of RMCT in Canada and disseminate novel developments and findings, thus significantly contributing to the world's knowledge in cellular therapeutics. As such, the CellCAN model could also serve as a useful benchmark to accelerate RMCT implementation in other countries.

Original languageEnglish (US)
Pages (from-to)24-28
Number of pages5
JournalStem Cells and Development
Volume23
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Regenerative Medicine
Cell- and Tissue-Based Therapy
Canada
Clinical Trials
Stem Cell Research
Benchmarking
Stem Cell Transplantation
Research
Industry
Economics
Research Personnel
Organizations

ASJC Scopus subject areas

  • Hematology
  • Developmental Biology
  • Cell Biology

Cite this

CellCAN : A unique enabler of regenerative medicine and cell therapy in Canada. / Roy, Denis Claude; Alarco, Anne Marie; Isasi, Rosario.

In: Stem Cells and Development, Vol. 23, 01.01.2014, p. 24-28.

Research output: Contribution to journalArticle

@article{a24ab451246b45018f87b94e9cb5cf6f,
title = "CellCAN: A unique enabler of regenerative medicine and cell therapy in Canada",
abstract = "Regenerative Medicine and Cell Therapy (RMCT) is paving the way for the most innovative and promising medical breakthroughs of the 21st century. Indeed, its curative potential is immense and builds on the already proven benefits of stem cell transplantation. Successful and broad clinical implementation of RMCT, as well as reaping of its full social and economic benefits, is contingent on the resolution of a range of issues. The CellCAN network, a not-for-profit corporation, was created to tackle these challenges, gathering the key forces of the numerous Canadian organizations involved in basic research, assay development, manufacturing, clinical research, clinical trials, legal and ethical regulations, and policies, all working to move RMCT forward. CellCAN creates a national enterprise by bringing together a community of renowned researchers, industries, clinicians, funders and regulators, and aligning it with cell-handling facilities involved in processing cell products and other products for cell therapy clinical trials to ensure capacity and know-how for stem cell research and efficient execution of cell therapy clinical trials. CellCAN is uniquely positioned to accelerate the implementation of RMCT in Canada and disseminate novel developments and findings, thus significantly contributing to the world's knowledge in cellular therapeutics. As such, the CellCAN model could also serve as a useful benchmark to accelerate RMCT implementation in other countries.",
author = "Roy, {Denis Claude} and Alarco, {Anne Marie} and Rosario Isasi",
year = "2014",
month = "1",
day = "1",
doi = "10.1089/scd.2014.0354",
language = "English (US)",
volume = "23",
pages = "24--28",
journal = "Stem Cells and Development",
issn = "1547-3287",
publisher = "Mary Ann Liebert Inc.",

}

TY - JOUR

T1 - CellCAN

T2 - A unique enabler of regenerative medicine and cell therapy in Canada

AU - Roy, Denis Claude

AU - Alarco, Anne Marie

AU - Isasi, Rosario

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Regenerative Medicine and Cell Therapy (RMCT) is paving the way for the most innovative and promising medical breakthroughs of the 21st century. Indeed, its curative potential is immense and builds on the already proven benefits of stem cell transplantation. Successful and broad clinical implementation of RMCT, as well as reaping of its full social and economic benefits, is contingent on the resolution of a range of issues. The CellCAN network, a not-for-profit corporation, was created to tackle these challenges, gathering the key forces of the numerous Canadian organizations involved in basic research, assay development, manufacturing, clinical research, clinical trials, legal and ethical regulations, and policies, all working to move RMCT forward. CellCAN creates a national enterprise by bringing together a community of renowned researchers, industries, clinicians, funders and regulators, and aligning it with cell-handling facilities involved in processing cell products and other products for cell therapy clinical trials to ensure capacity and know-how for stem cell research and efficient execution of cell therapy clinical trials. CellCAN is uniquely positioned to accelerate the implementation of RMCT in Canada and disseminate novel developments and findings, thus significantly contributing to the world's knowledge in cellular therapeutics. As such, the CellCAN model could also serve as a useful benchmark to accelerate RMCT implementation in other countries.

AB - Regenerative Medicine and Cell Therapy (RMCT) is paving the way for the most innovative and promising medical breakthroughs of the 21st century. Indeed, its curative potential is immense and builds on the already proven benefits of stem cell transplantation. Successful and broad clinical implementation of RMCT, as well as reaping of its full social and economic benefits, is contingent on the resolution of a range of issues. The CellCAN network, a not-for-profit corporation, was created to tackle these challenges, gathering the key forces of the numerous Canadian organizations involved in basic research, assay development, manufacturing, clinical research, clinical trials, legal and ethical regulations, and policies, all working to move RMCT forward. CellCAN creates a national enterprise by bringing together a community of renowned researchers, industries, clinicians, funders and regulators, and aligning it with cell-handling facilities involved in processing cell products and other products for cell therapy clinical trials to ensure capacity and know-how for stem cell research and efficient execution of cell therapy clinical trials. CellCAN is uniquely positioned to accelerate the implementation of RMCT in Canada and disseminate novel developments and findings, thus significantly contributing to the world's knowledge in cellular therapeutics. As such, the CellCAN model could also serve as a useful benchmark to accelerate RMCT implementation in other countries.

UR - http://www.scopus.com/inward/record.url?scp=84919396018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919396018&partnerID=8YFLogxK

U2 - 10.1089/scd.2014.0354

DO - 10.1089/scd.2014.0354

M3 - Article

C2 - 25457957

AN - SCOPUS:84919396018

VL - 23

SP - 24

EP - 28

JO - Stem Cells and Development

JF - Stem Cells and Development

SN - 1547-3287

ER -